Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Merck & Company Inc (MRK)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Merck&Co's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
93.00 +0.68    +0.74%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
93.00
0.00
0.00%
19:05:59 - Real-time Data
Type:  Equity
Market:  United States
ISIN:  US58933Y1055 
CUSIP:  58933Y105
  • Volume: 17,263,476
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 91.51 - 94.56
Merck&Co 93.00 +0.68 +0.74%
InvestingPro Advanced Ratios
Name Company Industry
   
P/E Ratio TTM 16.83 50.28
Price to Sales TTM 4.33 5.91
Price to Cash Flow MRQ 76.52 47.34
Price to Free Cash Flow TTM 38.45 46.01
Price to Book MRQ 5.71 8.7
Price to Tangible Book MRQ - 123.71
   
Profitability: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Gross margin TTM 71.11% 69.9
Gross Margin 5YA 70.92% 71.55
Operating margin TTM 28.85% -8.06
Operating margin 5YA 18.48% -23.39
Pretax margin TTM 29.18% -4.66
Pretax margin 5YA 19.9% -24.97
Net Profit margin TTM 25.78% -7.46
Net Profit margin 5YA 16.06% -26.62
   
Revenue/Share TTM 21.28 19.6
Basic EPS ANN 4.88 4.23
Diluted EPS ANN 4.86 4.19
Book Value/Share MRQ 16.17 15.73
Tangible Book Value/Share MRQ -1.34 -2.79
Cash/Share MRQ 3.53 5.72
Cash Flow/Share TTM 6.83 5.98
   
Management Effectiveness: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Return on Equity TTM 41.02% 30.47
Return on Equity 5YA 22.51% 26.71
Return on Assets TTM 14.09% 10.63
Return on Assets 5YA 7.61% 9.02
Return on Investment TTM 18.72% 16.21
Return on Investment 5YA 10.14% 12.86
   
EPS(MRQ) vs Qtr. 1 Yr. Ago MRQ 57.2% 145.95
EPS(TTM) vs TTM 1 Yr. Ago TTM 190.92% 55.28
5 Year EPS Growth 5YA 28.17% 10.49
Sales (MRQ) vs Qtr. 1 Yr. Ago MRQ 49.63% 26.26
Sales (TTM) vs TTM 1 Yr. Ago TTM 28.96% 23.88
5 Year Sales Growth 5YA 4.12% 7.08
5 Year Capital Spending Growth 5YA 22.48% 4.41
   
Quick Ratio MRQ 1.14 1.11
Current Ratio MRQ 1.4 1.73
LT Debt to Equity MRQ 74.81% 74.19
Total Debt to Equity MRQ 77.77% 88.81
Efficiency    
Asset Turnover TTM 0.55 0.51
Inventory Turnover TTM 2.56 2.44
Revenue/Employee TTM 793.79K 1.02M
Net Income/Employee TTM 204.65K 319.55K
Receivable Turnover TTM 5.98 6.39
   
Dividend Yield ANN 2.99% 3.06
Dividend Yield 5 Year Avg. 5YA 3.19% 2.82
Dividend Growth Rate ANN 9.88% 5.97
Payout Ratio TTM 48.94% 272.22
TTM = Trailing Twelve Months  5YA = 5-Year Average  MRQ = Most Recent Quarter
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced valuation and financial ratios for in-depth analysis of company financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MRK Comments

Write your thoughts about Merck & Company Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Daniel Rush
Daniel Rush 58 minutes ago
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Are you searching for a professional to trade with or learn more about trading? I recommend Melissa Anthony on Face💭book
Daniel Rush
Daniel Rush 4 hours ago
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Most times it amazes me greatly the way i moved from an average lifestyle to earning. over 64k per month, utter shock is the word. I have understood a lot in the past few months to doubt that opportunities abound in the financial markets, The only thing is to know where to focus. That's why I'm referring everyone of you out there to visit Melissa Anthony at Face📚book she's the best broker I've ever encountered with.
Ashutosh Mukharjee
Ashutosh Mukharjee 5 hours ago
Saved. See Saved Items.
This comment has already been saved in your Saved Items
From deep analysis we found that today very soon it's goes upward 🎯 target 109.35 SL- 92.45
black cat
black cat May 16, 2022 12:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ma e' sui massimi da sempre? che t.p. si puo' immaginare a questo punto ?
Rob Roo
Rob Roo Apr 28, 2022 1:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀🚀🚀🚀🚀🚀🚀🌜
Taras Khomitsky
Taras Khomitsky Apr 28, 2022 8:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good, even great reasults in first quater of 2022.Let's hope to go back to 86-87 territory
Fever Factory
Fever Factory Apr 20, 2022 5:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention.
Fever Factory
Fever Factory Apr 20, 2022 5:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
Fever Factory
Fever Factory Apr 20, 2022 5:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
William Hineser
William Hineser Apr 02, 2022 9:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It was 22 in 1995. Do the math and look at the products.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email